Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06387212
Other study ID # HUI0001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 15, 2024
Est. completion date May 2024

Study information

Verified date April 2024
Source Nakhia Impex LLC
Contact Mizhou Hui
Phone 13484005199
Email mizhou.hui@alumni.utoronto.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To explore the clinical effect and safety of 35 kDa hyaluronic acid fragment ( HA35 ) combined with negative pressure microneedle technology in improving skin problems.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date May 2024
Est. primary completion date May 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Skin problems include but are not limited to dry skin, dark skin, and coarse pores. - Chronic skin inflammation, pigmentation, erythema, etc. - Cooperate with the experimental requirements and be able to complete the score independently? Exclusion Criteria: - Pregnant or lactating women. - Suffering from psychological or mental illness. - Life is not regular, overeating. - Hypersensitive to hyaluronic acid, and has a scar constitution.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
35 kDa hyaluronan fragment HA35 injection
First, apply an appropriate amount of compound lidocaine cream to the treatment site ( national drug approval number H20063466 ; Beijing Ziguang Pharmaceutical Co., Ltd. ) waited for 60 minutes after applying hemp, and then injected the syringe containing sterile HA35 prepared in advance into the subcutaneous 1.0-1.5mm through the DermaShine PRO negative pressure microneedle importer ( Demasha, South Korea ).

Locations

Country Name City State
Mongolia Nahia Impex LLC Ulaanbaatar

Sponsors (1)

Lead Sponsor Collaborator
Nakhia Impex LLC

Country where clinical trial is conducted

Mongolia, 

Outcome

Type Measure Description Time frame Safety issue
Primary A skin dryness scale The Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents no skin dryness, while 10 represents the worst degree of skin dryness. 120 minutes and 960 minutes
Primary A fair or smooth skin scale The Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents the worse degree of fair or smooth skin, while 10 represents the best degree of fair or smooth skin. 120 minutes and 960 minutes
Primary A skin pore size scale The Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents the best degree of skin pore size, while 10 represents the worst degree of skin pore size. 120 minutes and 960 minutes
Primary A inflammatory skin thick hardness scale The Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents the best degree of inflammatory skin thick hardness, while 10 represents the worst degree of inflammatory skin thick hardness. 120 minutes and 960 minutes
Primary An erythema color and area scale The Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents the best degree of erythema color and area, while 10 represents the worst degree of erythema color and area scale. 120 minutes and 960 minutes
Secondary Self-satisfaction evaluation One week after the end of the treatment, a return visit was conducted to collect the overall satisfaction score of the subjects on the skin treatment. Using the questionnaire (0-10 score) to assess this outcome measure. 0 represents the most dissatisfied, while 10 represents the most satisfied. 1 week after the end of the treatment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04479514 - Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy Phase 2
Completed NCT03065504 - Turmeric and Turmeric-containing Tablets and Sebum Production N/A
Recruiting NCT05535738 - Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Phase 2/Phase 3
Recruiting NCT05277324 - The Effect of Wearing Facial Masks on Skin Parameters During the COVID-19 Pandemic
Completed NCT05300542 - Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced Erythema N/A
Completed NCT05745636 - Broccoli Seed Extract and Skin Health N/A
Completed NCT03192280 - Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response N/A
Withdrawn NCT03976206 - Very Small Embryonic-like Stem Cells for Facial Skin Antiaging Phase 1/Phase 2
Completed NCT05102604 - The Effect of Avocado vs. Usual Diet on Skin Aging N/A
Withdrawn NCT03862872 - Effects of Bend Beauty's Anti-Aging Formula on Inflammatory Markers N/A
Completed NCT04471896 - Joovvin' for Your Skin Health Study N/A
Recruiting NCT03581747 - Detection of Skin Epithelial Barrier in Patients With Allergic Skin Disorders
Completed NCT05517720 - An Exploratory Investigation of a Novel Skincare Regimen N/A
Completed NCT05461456 - Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1% Phase 1